ARYX » Topics » ARYx THERAPEUTICS, INC.

These excerpts taken from the ARYX 8-K filed Nov 12, 2009.

ARYx THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33782

 

77-0456039

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer Identification No.)

of incorporation)

 

 

 

 

 

6300 Dumbarton Circle
Fremont, California

 

94555

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:

About ARYx Therapeutics, Inc.

 

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical development: an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (ATI-2042); an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (ATI-5923); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit ARYx’s Website at www.aryx.com for additional information.

 

3



 

This excerpt taken from the ARYX 8-K filed Nov 2, 2009.

About ARYx Therapeutics, Inc.

 

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical development: an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (previously ATI-2042); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (previously ATI-5923); and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit the ARYx Website at www.aryx.com for additional information.

 

These excerpts taken from the ARYX 8-K filed Oct 8, 2009.

ARYx THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33782

 

77-0456039

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer Identification No.)

of incorporation)

 

 

 

 

 

 

 

 

 

6300 Dumbarton Circle
Fremont, California

 


94555

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:

About ARYx Therapeutics, Inc.

 

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical development: an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (previously ATI-2042); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (previously ATI-5923); and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit the ARYx Website at www.aryx.com for additional information.

 

These excerpts taken from the ARYX 8-K filed Aug 13, 2009.

ARYX THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33782

 

77-0456039

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer Identification No.)

of incorporation)

 

 

 

 

 

 

 

 

 

6300 Dumbarton Circle

Fremont, California

 

94555

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:

About ARYx Therapeutics, Inc.

 

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical development: an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (previously named ATI-2042); an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (previously named ATI-5923); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit ARYx’s Website at www.aryx.com for additional information.

 

These excerpts taken from the ARYX 8-K filed Jul 8, 2009.

ARYx THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33782

 

77-0456039

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer Identification No.)

of incorporation)

 

 

 

 

 

 

 

 

 

6300 Dumbarton Circle

 

 

Fremont, California

 

94555

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:

About ARYx Therapeutics, Inc.

 

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical development: an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (previously ATI-5923); an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (previously ATI-2042); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit the ARYx Website at www.aryx.com for additional information.

 

This excerpt taken from the ARYX 8-K filed May 27, 2009.

ARYx THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33782

 

77-0456039

 

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

 

of incorporation)

 

 

 

 

 

 

 

 

 

 

6300 Dumbarton Circle

 

 

 

 

Fremont, California

 

94555

(Address of principal executive offices)

 

(Zip Code)

 

 

Registrant’s telephone number, including area code: (510) 585-2200

 

These excerpts taken from the ARYX 8-K filed May 14, 2009.

ARYx THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33782

 

77-0456039

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer Identification No.)

of incorporation)

 

 

 

 

 

 

 

 

 

6300 Dumbarton Circle
Fremont, California

 

94555

(Address of principal executive offices)

 

(Zip Code)

 

 

Registrant’s telephone number, including area code:

About ARYx Therapeutics, Inc.

 

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical trials: an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (previously named ATI-5923); an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (previously named ATI-2042); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit our web site at www.aryx.com for additional information.

 

This excerpt taken from the ARYX 10-Q filed May 14, 2009.

ARYx THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

77-0456039

(State or Other Jurisdiction of
Incorporation or Organization)

 

(I.R.S. Employer
Identification No.)

 

These excerpts taken from the ARYX 8-K filed Mar 26, 2009.

ARYx THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33782

 

77-0456039

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer Identification No.)

of incorporation)

 

 

 

 

 

 

 

 

 

6300 Dumbarton Circle
Fremont, California

 

94555

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:

About ARYx Therapeutics, Inc.

 

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical trials: an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (previously named ATI-5923); an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (previously named ATI-2042); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit our web site at www.aryx.com for additional information.

 

This excerpt taken from the ARYX 8-K filed Feb 24, 2009.

ARYX THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33782

 

77-0456039

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer Identification No.)

of incorporation)

 

 

 

 

 

6300 Dumbarton Circle Fremont, California

 

94555

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:

This excerpt taken from the ARYX 8-K filed Feb 10, 2009.

ARYx THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33782

 

77-0456039

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer Identification No.)

of incorporation)

 

 

 

 

 

 

 

 

 

6300 Dumbarton Circle
Fremont, California

 

94555

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:

These excerpts taken from the ARYX 8-K filed Jan 12, 2009.

ARYx THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-33782

 

77-0456039

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer Identification No.)

of incorporation)

 

 

 

 

 

 

 

 

 

6300 Dumbarton Circle
Fremont, California

 


94555

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:

About ARYx Therapeutics, Inc.

 

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with

 

3



 

well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical trials: an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, ATI-5923; an oral anti-arrhythmic agent for the treatment of atrial fibrillation, ATI-2042; a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit our web site at www.aryx.com for additional information.

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki